Pharmacokinetics of verapamil in diabetic rats induced by combination of high-fat diet and streptozotocin injection

Xenobiotica

Volumn 41, Issue 6, 2011, Pages 494-500

  Chen, G ^a   Hu, N ^a   Liu, L ^a   Xie, S S ^a   Wang, P ^a   Li, J ^a   Xie, L ^a   Wang, G J ^a   Liu, X D ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

CYP3A; Diabetes; insulin resistance; pharmacokinetics; verapamil

Indexed keywords

CYTOCHROME P450 3A2; NORVERAPAMIL; STREPTOZOCIN; VERAPAMIL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME INDUCTION; LIPID DIET; LIVER MICROSOME; MALE; MEAN RESIDENCE TIME; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; RAT; WESTERN BLOTTING;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; CYTOCHROME P-450 CYP3A; DIABETES MELLITUS, EXPERIMENTAL; DIET; DIETARY FATS; DISEASE MODELS, ANIMAL; INJECTIONS, INTRAVENOUS; LIVER; MALE; MICROSOMES, LIVER; RATS; RATS, SPRAGUE-DAWLEY; STREPTOZOCIN; VERAPAMIL;

RATTUS;

EID: 79956363660     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2011.558933     Document Type: Article

References (31)

1. Afzal N, Ganguly PK, Dhalla KS, Pierce GN, Singal PK, Dhalla NS. (1988). Benefcial efects of verapamil in diabetic cardiomyopathy. Diabetes 37:936-942. (Pubitemid 19043725)
2. Andersson DE, Röjdmark S. (1981). Improvement of glucose tolerance by verapamil in patients with non-insulin-dependent diabetes mellitus. Acta Med Scand 210:27-33. (Pubitemid 11002638)
3. Bonora E, Targher G, Alberiche M, Bonadonna RC, Saggiani R, Zenere MB, Monauni T, Muggeo M. (2000). Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 23:57-63. (Pubitemid 30022895)
4. Bradford MM. (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
5. Choi JS, Burm JP. (2005). Pharmacokinetics of verapamil and its major metabolite, norverapamil from oral administration of verapamil in rabbits with hepatic failure induced by carbon tetrachloride. Arch Pharm Res 28:483-487.
6. Fleckenstein A. (1977). Specifc pharmacology of calcium in myocardium, cardiac pacemarkers, and vascular smooth muscle. Ann Rev Pharmacol Toxicol 17:149-166.
7. Gould BA, Mann S, Kieso H, Subramanian VB, Raftery EB. (1982). Te 24-hour ambulatory blood pressure profle with verapamil. Circulation 65:22-27. (Pubitemid 12250885)
8. Hu N, Xie S, Liu L, Wang X, Pan X, Chen G, Zhang L, Liu H, Liu X, Liu X, Xie L, Wang G. (2010). Opposite Efect of Diabetes Mellitus Induced by Streptozotocin on Oral and Intravenous Pharmacokinetics of Verapamil in Rats. Drug Metab Dispos (In Press).
9. Irizar A, Ioannides C. (1998). Marked inhibition of hepatic cytochrome P450 activity in cholesterol-induced atherosclerosis in rabbits. Toxicology 126:179-193. (Pubitemid 28281141)
10. Kameyama N, Arisawa S, Ueyama J, Kagota S, Shinozuka K, Hattori A, Tatsumi Y, Hayashi H, Takagi K, Wakusawa S. (2008). Increase in P-glycoprotein accompanied by activation of protein kinase Calpha and NF-kappaB p65 in the livers of rats with streptozotocin-induced diabetes. Biochim Biophys Acta 1782:355-360.
11. Kim YC, Lee AK, Lee JH, Lee I, Lee DC, Kim SH, Kim SG, Lee MG. (2005). Pharmacokinetics of theophylline in diabetes mellitus rats: induction of CYP1A2 and CYP2E1 on 1,3-dimethyluric acid formation. Eur J Pharm Sci 26:114-123. (Pubitemid 41097268)
12. Kroemer HK, Gautier JC, Beaune P, Henderson C, Wolf CR, Eichelbaum M. (1993). Identifcation of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol 348:332-337. (Pubitemid 23271638)
13. Kudo T, Shimada T, Ushiki T, Ohi K, Ikarashi N, Ochiai W, Sugiyama K. (2010). Diferences in the pharmacokinetics of Cyp3a substrates in TSOD and Streptozotocin-induced diabetic mice. Xenobiotica 39:889-902.
14. Kudo T, Toda T, Ushiki T, Ohi K, Ikarashi N, Ochiai W, Sugiyama K. (2009). Altered expression of CYP in TSOD mice: a model of type 2 diabetes and obesity. Xenobiotica 40:282-290.
15. Lucas D, Farez C, Bardou LG, Vaisse J, Attali JR, Valensi P. (1998). Cytochrome P450 2E1 activity in diabetic and obese patients as assessed by chlorzoxazone hydroxylation. Fundam Clin Pharmacol 12:553-558. (Pubitemid 29166500)
16. Marques MP, Coelho EB, Dos Santos NA, Geleilete TJ, Lanchote VL. (2002). Dynamic and kinetic disposition of nisoldipine enantiomers in hypertensive patients presenting with type-2 diabetes mellitus. Eur J Clin Pharmacol 58:607-614. (Pubitemid 35478187)
17. Matzke GR, Frye R F, Early JJ, Straka RJ, Carson SW. (2000). Evaluation of the infuence of diabetes mellitus on antipyrine metabolism and CYP1A2 and CYP2D6 activity. Pharmacotherapy 20:182-190. (Pubitemid 30073838)
18. Padwal R, Majumdar SR, Johnson JA, Varney J, McAlister FA. (2005). A systematic review of drug therapy to delay or prevent type 2 diabetes. Diabetes Care 28:736-744. (Pubitemid 40315342)
19. Reed MJ, Meszaros K, Entes LJ, Claypool MD, Pinkett JG, Gadbois TM, Reaven GM. (2000). A new rat model of type 2 diabetes: the fat-fed, streptozotocin-treated rat. Metab Clin Exp 49:1390-1394.
20. Shimojo N, Ishizaki T, Imaoka S, Funae Y, Fujii S, Okuda K. (1993). Changes in amounts of cytochrome P450 isozymes and levels of catalytic activities in hepatic and renal microsomes of rats with streptozocin-induced diabetes. Biochem Pharmacol 46:621-627. (Pubitemid 23262955)
21. Shimojo N. (1994). Cytochrome P450 changes in rats with streptozocin-induced diabetes. Int J Biochem 26:1261-1268. (Pubitemid 24358571)
22. Srinivasan K, Viswanad B, Asrat L, Kaul CL, Ramarao P. (2005). Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: a model for type 2 diabetes and pharmacological screening. Pharmacol Res 52:313-320. (Pubitemid 41175991)
23. Stewart CC, Strother A. (1999). Glucose consumption by rats decreases cytochrome P450 enzyme activity by altering hepatic lipids. Life Sci 64:2163-2172. (Pubitemid 29236576)
24. Sotaniemi EA, Pelkonen O, Arranto AJ, Tapanainen P, Rautio A, Pasanen M. (2002). Diabetes and elimination of antipyrine in man: an analysis of 298 patients classifed by type of diabetes, age, sex, duration of disease and liver involvement. Pharmacol Toxicol 90:155-160. (Pubitemid 34289614)
25. Tummel KE, Wilkinson GR. (1998). In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol 38:389-430. (Pubitemid 28231501)
26. Ueyama J, Wang D, Kondo T, Saito I, Takagi K, Takagi K, Kamijima M, Nakajima T, Miyamoto K, Wakusawa S, Hasegawa T. (2007). Toxicity of diazinon and its metabolites increases in diabetic rats. Toxicol Lett 170:229-237. (Pubitemid 46710274)
27. Ueyama J, Kamijima M, Asai K, Mochizuki A, Wang D, Kondo T, Suzuki T, Takagi K, Takagi K, Kanazawa H, Miyamoto K, Wakusawa S, Hasegawa T. (2008). Efect of the organophosphorus pesticide diazinon on glucose tolerance in type 2 diabetic rats. Toxicol Lett 182:42-47.
28. Vogeser M, König D, Frey I, Predel HG, Parhofer KG, Berg A. (2007). Fasting serum insulin and the homeostasis model of insulin resistance (HOMA-IR) in the monitoring of lifestyle interventions in obese persons. Clin Biochem 40:964-968. (Pubitemid 47301794)
29. Wang Z, Hall SD, Maya J F, Li L, Asghar A, Gorski JC. (2003). Diabetes mellitus increases the in vivo activity of cytochrome P450 2E1 in humans. Br J Clin Pharmacol 55:77-85. (Pubitemid 36110842)
30. Watson AM, Poloyac SM, Howard G, Blouin RA. (1999). Efect of leptin on cytochrome P-450, conjugation, and antioxidant enzymes in the ob/ob mouse. Drug Metab Dispos 27:695-700. (Pubitemid 29252444)
31. Xie SS, Hu N, Jing XY, Liu XD, Xie L, Wang GJ, Liu CH. (2010). Efect of Huang-Lian-Jie-Du-Decoction on pharmacokinetics of verapamil in rats. J Pharm Pharmacol 62:440-447.